Back to Results

Quoin Pharmaceuticals Ltd DRC (QNRX)

Quoin Pharmaceuticals Ltd DRC (NASDAQ: QNRX) is a depositary receipt tied to Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases in the United States. The company’s lead program is QRX003, a topical lotion being developed for Netherton Syndrome. Its pipeline also includes QRX004 for recessive dystrophic epidermolysis bullosa, QRX007 for Netherton Syndrome, and QRX008 for scleroderma. Quoin has research and licensing relationships with Queensland University of Technology, Skinvisible Inc., Axella Research LLC, and Therapeutics Inc. Founded in 2018 and based in Ashburn, Virginia, Quoin Pharmaceuticals is a subsidiary of Skinvisible, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-QNRX
$6.36
-9.9% Downside
Fair
$22.20
214.4% Upside
Bargain
Fair
0.0%
November 13, 2026
3.6x
14.179 M
5.403 M
12.4%
64.8%
-13.6
81.8%
Valuation • Fair Value

Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) Fair Value by Valuation Model

Review the available estimates for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$6.36

Estimated downside of 9.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.22

Discounted cash flow valuation reference.

Comps Fair Value

$7.12

Comparable-company valuation reference.

Analyst Price Target

$22.20

Analysts imply upside of 214.4%.

How to read these valuation models

Use the 5 available valuation references for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-19.045 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-13.6

Lower score that deserves closer risk review.

FCF / Net Income

81.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) Stock Forecast & Technical Outlook

Review Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) Stock FAQ

Data-supported answers about Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.36
Estimated downside 9.9%
Valuation Rating
Overvalued
Estimated downside of 9.9%
Analyst Target
$22.20
Implied upside 214.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is $6.36. This implies an estimated downside of 9.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 9.9% versus the current market price.

The available analyst price target for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is $22.20. The analyst target implies estimated upside of 214.4%.

The current financial health read for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is November 13, 2026.

The latest available data indicates no current dividend yield for Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX).

The current market capitalization listed for Quoin Pharmaceuticals Ltd DRC is 14.179 M.

The current enterprise value listed for Quoin Pharmaceuticals Ltd DRC is 5.403 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Quoin Pharmaceuticals Ltd DRC is NASDAQ-QNRX, and the stock is listed on NASDAQ.

Quoin Pharmaceuticals Ltd DRC (NASDAQ-QNRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Quoin Pharmaceuticals Ltd DRC is 12.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Quoin Pharmaceuticals Ltd DRC is 64.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B